$100+ billion deals?, page-121

Duku

the use of standard HIV antivirals, mostly Kalentra branded, has been the principle medication in the severest cases so far. This is because they proved beneficial with SARS, although not entirely.

nCoV is not SARS, and has remarkable differences that are quite worrying that no researcher yet has been able to shed any light on the structure that causes these differences.

Remdesivir, is another antiviral being tested presently in China, and if successful, will most likely displace Kalentra. But there still isn't any news on these tests yet.

Bioton's antivirals are just as potentially beneficial, and are no less further in testing on nCoV than Remdesiver is, apart from the fact that the later is being tested in China, and not Australia. Frankly, this difference doesn't necessarily favour China's ability in their tests when Biotron has access to the cloned new virus. One could equally argue that Biotron is sitting better here.

Regardless, BIT's share price is responding to the market, which is the collective sentiment of all investors, including those who might have researched better than most HC traders.